{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:32Z","timestamp":1786120352616,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1097\/mbc.0b013e3283504118","type":"journal-article","created":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T07:09:47Z","timestamp":1328684987000},"page":"262-267","source":"Crossref","is-referenced-by-count":5,"title":["Use of objective efficacy criteria for evaluation of von willebrand factor\/factor VIII concentrates"],"prefix":"10.1097","volume":"23","author":[{"given":"Craig M.","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"Knaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/MBC.0b013e32832c8803","article-title":"Challenges of defining reliable clinical surrogate end points in haemophilia trials: a critical review.","volume":"20","author":"Amby","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"Suppl 3","key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease.","volume":"4","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1612977","article-title":"Efficacy and safety of the factor VIIIvon Willebrand factor concentrate, haemate-Phumate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.","volume":"87","author":"Lillicrap","year":"2002","journal-title":"Thromb Haemost"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3324\/haematol.11124","article-title":"Clinical use of Haemate P in inherited von Willebrands disease: a cohort study on 100 Italian patients.","volume":"92","author":"Federici","year":"2007","journal-title":"Haematologica"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2516.2002.00688.x","article-title":"Clinical efficacy of highly purified, doubly virus-inactivated factor VIIIvon Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","article-title":"Efficacy and safety of highly purified, doubly virus-inactivated VWFFVIII concentrates in inherited von Willebrands disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.","volume":"16","author":"Federici","year":"2010","journal-title":"Haemophilia"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1351-8216.2003.00809.x","article-title":"Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIIIVWF concentrate (Humate-P).","volume":"10","author":"Thompson","year":"2004","journal-title":"Haemophilia"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1351-8216.2003.00816.x","article-title":"Successful treatment of urgent bleeding in von Willebrand disease with factor VIIIVWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.","volume":"9","author":"Gill","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl 5","key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2007.01570.x","article-title":"Fanhdi, efficacy and safety in von Willebrands disease: prospective international study results.","volume":"13","author":"Bello","year":"2007","journal-title":"Haemophilia"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease: efficacy and safety of Wilate(, a new generation von Willebrand factorfactor VIII concentrate.","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1160\/TH11-02-0057","article-title":"The pharmacokinetic diversity of two von Willebrand factor (VWF) factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.","volume":"106","author":"Kessler","year":"2011","journal-title":"Thromb Haemost"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIIIvon Willebrand factor concentrate: a prospective, multicenter study.","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MBC.0b013e3283504118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:35:04Z","timestamp":1786048504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001721-201206000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e3283504118","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}